BRISTOL

📅 Upcoming

🕒 Recent(90d)

News

• STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
  A major Novartis shareholder has called for a shake-up of the drugmaker's board after its shares suffered a record fall following trial setbacks
  stat · 13h ago
• STAT+: Cancer medicines remain in short supply across the U.S., survey finds
  An ongoing shortage of cancer medications continues to force leading cancer centers around the U.S. to seek work-around strategies to treat patients and a majority also report that clinical trials…
  stat · 13h ago
• Tyra shares slip as bladder cancer responses fall short of investor expectations
  Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.
  biospace · 13h ago
• Merck adds 53 to New Jersey chopping block
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
  An AstraZeneca drug reduced the dangerous flare-ups that worsen COPD in a pair of late-stage trials
  stat · 1d ago
• BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
  Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, accordin…
  biospace · 1d ago
• Beeline Medicines reports promising Phase 2 lupus data
  The business of advancing shelved pharma assets continues to reap benefits, this time for Beeline Medicines and a lupus candidate provided by Bristol Myers Squibb. The buzzy Bain-backed startup sai…
  endpoints · 1d ago
• A new immuno-oncology play raises $225M for a next-generation drug
  Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
  biopharma_dive · 1d ago
• Beeline flies into phase 3 as oral lupus drug soars past placebo
  A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
  fiercebiotech · 1d ago
• Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
  Solstice Oncology has secured $225 million in series A funding to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer care.
  fiercebiotech · 2d ago